Abbott Q3 Report 2023

“The investments we made during the pandemic continue to drive broad-based growth across our underlying base business,” said Robert B. Ford, chairman and chief executive officer, Abbott. “We’re on track to deliver on the financial commitments we set at the beginning of the year, and the momentum we’re building across the portfolio positions us well as we head into 2024.”

Abbott Financial Result

• Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items.
• Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and projects adjusted diluted EPS of $4.42 to $4.46, which represents an increase at the midpoint of the guidance range.
• Abbott continues to project full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, to be in the low double-digits.

.